David Kideckel

Director of Finance/CFO at RAKOVINA THERAPEUTICS INC.

Net worth: 10 080 $ as of 31/07/2026

Finance

Consumer Services

Health Technology

Profile

David M.
Kideckel is the founder of Kideckel Advisory Group, Inc., founded in 2021, where the title held is President & Chief Executive Officer.
Current jobs include Executive Chairman at Pharmadrug, Inc. starting in 2025; Director at Kane Biotech, Inc. starting in 2025; Chief Financial Officer & Director at Rakovina Therapeutics, Inc. starting in 2025; and EVP, Head-Strategy & Corporate Development at Delta 9 Cannabis, Inc. starting in 2021.
Former jobs include Analyst & Managing Director at ATB Cormark Capital Markets Inc. from 2018 to 2021; Director of Equity Research at Beacon Securities Limited from 2017 to 2018; Principal at Origin Merchant Partners from 2022 to 2023; and Senior VP, Head-Corporate Development & Strategic at IntelGenx Technologies Corp.
Education includes an MBA from Rotman School of Management and a doctorate from the University of Toronto.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
PHARMADRUG, INC. 1.03%	09/10/2025	13,80,000 ( 1.03% )	8 280 $	31/07/2026
RAKOVINA THERAPEUTICS INC 0.09%	29/07/2025	20,000 ( 0.09% )	1 800 $	31/07/2026
KANE BIOTECH INC. -.--%	28/05/2026	0 ( -.--% )	- $	31/07/2026

David Kideckel active positions

Companies	Position	Start
HUMBLE GROW CO.	Corporate Officer/Principal	16/08/2021
PHARMADRUG INC.	Chairman	27/02/2024
RAKOVINA THERAPEUTICS INC.	Director of Finance/CFO	01/05/2025
KANE BIOTECH INC.	Director/Board Member	25/06/2025

All active positions of David Kideckel

Former positions of David Kideckel

Companies	Position	End
Origin Merchant Partners Origin Merchant Partners Investment Banks/BrokersFinance Provides investment banking services	Corporate Officer/Principal	01/01/2023
ATB Cormark Capital Markets Inc. ATB Cormark Capital Markets Inc. Investment Banks/BrokersFinance Provides brokerage services	Analyst-Equity	01/08/2021
Beacon Securities Ltd. Beacon Securities Ltd. Investment Banks/BrokersFinance Provides brokerage services	Director of Research - Equity	01/10/2018
INTELGENX TECHNOLOGIES CORP.	Corporate Officer/Principal	-

See the detail of David Kideckel's experience

Training of David Kideckel

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Kideckel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	10
Kane Biotech, Inc. Kane Biotech, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that manufactures animal health oral care products	Commercial Services
Rotman School of Management Rotman School of Management Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
ATB Cormark Capital Markets Inc. ATB Cormark Capital Markets Inc. Investment Banks/BrokersFinance Provides brokerage services	Finance
University of Toronto University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Beacon Securities Ltd. Beacon Securities Ltd. Investment Banks/BrokersFinance Provides brokerage services	Finance
IntelGenx Technologies Corp. IntelGenx Technologies Corp. Pharmaceuticals: MajorHealth Technology Operates as a drug delivery company that develops and manufactures oral film therapeutics	Health Technology
Origin Merchant Partners Origin Merchant Partners Investment Banks/BrokersFinance Provides investment banking services	Finance
Delta 9 Cannabis, Inc. Delta 9 Cannabis, Inc. Wholesale DistributorsDistribution Services Wholesales and retails cannabis products	Distribution Services
Pharmadrug, Inc. Pharmadrug, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development of cannabis-infused edible products and oil extracts	Health Technology
Rakovina Therapeutics, Inc. Rakovina Therapeutics, Inc. Financial ConglomeratesFinance Develops oncology therapeutics	Finance